Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials
Abstract Skeletal muscle tissue (SKM) may be damaged due to mechanical, metabolic, and exertional causes. However, drug-induced myopathy is among the most frequent causes of muscle disease. The clinical picture of drug-induced myopathies may be highly variable. It may present as asymptomatic or mild myalgias, with or without muscle weakness, which are likely underreported. However, it may also appear as chronic myopathy with severe weakness and, rarely, even as massive rhabdomyolysis with acute kidney injury (AKI). Unfortunately, the available biomarkers for SKM injury do not fully meet the needs for satisfactory detection of drug-induced damage, both in clinical and research settings, mainly due to their low sensitivity and specificity. Therefore, the present study proposes a strategy for drug safety monitoring using the available biomarkers of SKM injury. Moreover, we will discuss mechanisms of drug-induced SKM injury, traditional laboratory testing for SKM injury, and novel skeletal myocyte biomarkers under investigation. This can be incredibly useful in both clinical practice and for de-challenge/re-challenge investigational trials where the risk of drug-induced SKM injury is present..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 61(2023), 10 vom: 16. Mai, Seite 1688-1699 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ostrowski, Patryk [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2023 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/cclm-2023-0313 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY009181466 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY009181466 | ||
| 003 | DE-627 | ||
| 005 | 20240126004603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230830s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2023-0313 |2 doi | |
| 035 | |a (DE-627)GRUY009181466 | ||
| 035 | |a (DE-B1597)cclm-2023-0313-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.46 |2 bkl | ||
| 100 | 1 | |a Ostrowski, Patryk |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Abstract Skeletal muscle tissue (SKM) may be damaged due to mechanical, metabolic, and exertional causes. However, drug-induced myopathy is among the most frequent causes of muscle disease. The clinical picture of drug-induced myopathies may be highly variable. It may present as asymptomatic or mild myalgias, with or without muscle weakness, which are likely underreported. However, it may also appear as chronic myopathy with severe weakness and, rarely, even as massive rhabdomyolysis with acute kidney injury (AKI). Unfortunately, the available biomarkers for SKM injury do not fully meet the needs for satisfactory detection of drug-induced damage, both in clinical and research settings, mainly due to their low sensitivity and specificity. Therefore, the present study proposes a strategy for drug safety monitoring using the available biomarkers of SKM injury. Moreover, we will discuss mechanisms of drug-induced SKM injury, traditional laboratory testing for SKM injury, and novel skeletal myocyte biomarkers under investigation. This can be incredibly useful in both clinical practice and for de-challenge/re-challenge investigational trials where the risk of drug-induced SKM injury is present. | ||
| 700 | 1 | |a Bonczar, Michał |0 (orcid)0000-0003-2080-165X |4 aut | |
| 700 | 1 | |a Avram, Aida-Elena |4 aut | |
| 700 | 1 | |a Lippi, Giuseppe |0 (orcid)0000-0001-9523-9054 |4 aut | |
| 700 | 1 | |a Henry, Brandon M. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d De Gruyter, 1998 |g 61(2023), 10 vom: 16. Mai, Seite 1688-1699 |h Online-Ressource |w (DE-627)GRUY000051497 |w (DE-600)1492732-9 |w (DE-576)088704882 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:10 |g day:16 |g month:05 |g pages:1688-1699 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/cclm-2023-0313 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.46 |j Klinische Pathologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 10 |b 16 |c 05 |h 1688-1699 | ||